EMAIL THIS PAGE TO A FRIEND

Bioorganic & medicinal chemistry

Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).


PMID 21955456

Abstract

The proton-coupled amino acid transporter hPAT1 has recently gained much interest due to its ability to transport small drugs thereby allowing their oral administration. A three-dimensional quantitative structure-activity relationship (3D QSAR) study has been performed on its natural and synthetic substrates employing comparative molecular similarity indices analysis (CoMSIA) to investigate the structural requirements for substrates and to derive a predictive model that may be used for the design of new prodrugs. The cross-validated CoMSIA models have been derived from a training set of 40 compounds and the predictive ability of the resulting models has been evaluated against a test set of 10 compounds. Despite the relatively narrow range of binding affinities (K(i) values) reliable statistical models with good predictive power have been obtained. The best CoMSIA model in terms of a proper balance of all statistical terms and the overall contribution of individual properties has been obtained by considering steric, hydrophobic, hydrogen bond donor and acceptor descriptors (q(cv)(2)=0.683, r(2)=0.958 and r(PRED)(2)=0.666). The 3D QSAR model provides insight in the interactions between substrates and hPAT1 on the molecular level and allows the prediction of affinity constants of new compounds. A pharmacophore model has been generated from the training set by means of the MOE (molecular operating environment) program. This model has been used as a query for virtual screening to retrieve potential new substrates from the small-molecule, 'lead-like' databases of MOE. The affinities of the compounds were predicted and 11 compounds were identified as possible high-affinity substrates. Two selected compounds strongly inhibited the hPAT mediated l-[(3)H]proline uptake into Caco-2 cells constitutively expressing the transport protein.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

O6254
(R)-(−)-2-Oxothiazolidine-4-carboxylic acid, ≥98% (titration), ≥97% (TLC)
C4H5NO3S
186511
(S)-(+)-2-Pyrrolidinemethanol, 97%
C5H11NO
850993
2-Aminoisobutyric acid, 98%
C4H9NO2
P42800
2-Picolinic acid, ReagentPlus®, 99%
C6H5NO2
127671
3-Aminobenzoic acid, 98%
C7H7NO2
G6878
3-Guanidinopropionic acid
C4H9N3O2
M2383
α-(Methylamino)isobutyric acid, ≥97% (titration)
C5H11NO2
08280
α-Aminoisobutyric acid, puriss., ≥99.0% (NT)
C4H9NO2
H5877
cis-4-Hydroxy-D-proline
C5H9NO3
H1637
cis-4-Hydroxy-L-proline, collagen synthesis inhibitor
C5H9NO3
A7377
D-Alanine, ≥98% (HPLC)
C3H7NO2
851620
D-Norvaline, 99%
C5H11NO2
268062
D-Pipecolinic acid, 99%
C6H11NO2
858919
D-Proline, ReagentPlus®, ≥99%
C5H9NO2
V1255
D-Valine, suitable for cell culture, BioReagent
C5H11NO2
855987
D-Valine, ≥98%
C5H11NO2
G11608
Guanidineacetic acid, 99%
C3H7N3O2
I18008
Isonipecotic acid, 97%
C6H11NO2
T27502
L-4-Thiazolidinecarboxylic acid, 98%
C4H7NO2S
A0760
L-Azetidine-2-carboxylic acid, ≥99%
C4H7NO2
C1159
L-Cycloserine
C3H6N2O2
N7627
L-Norvaline, arginase inhibitor
C5H11NO2
P2519
L-Pipecolic acid, 99% (titration)
C6H11NO2
237752
L-Pipecolic acid, Proline homolog., 99%
C6H11NO2
02676
N-Methyl-L-alanine, ≥98.0% (TLC)
C4H9NO2
80640
Piperidine, puriss. p.a., ≥99.0% (GC/T)
C5H11N
83240
Pyrrolidine, puriss. p.a., ≥99.0%
C4H9N
394238
Pyrrolidine, ≥99.5%, purified by redistillation
C4H9N
P73803
Pyrrolidine, 99%
C4H9N